Hemab Therapeutics Holdings shares are trading higher after the company announced it will present clinical and preclinical data from multiple blood coagulation programs at ISTH 2026.

Benzinga Newsdesk www.benzinga.com Positive 94.6%

Neg 0% Neu 0% Pos 94.6%

Comments

No comments yet. Be the first!